Susana G. Kalko

Vall d'Hebron Institut de Recerca — Spain

Medicine · Health Sciences

33h-index3.5kcitations126works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(29), Lymphoma Diagnosis and Treatment(24), Chronic Obstructive Pulmonary Disease (COPD) Research(14), Prostate Cancer Treatment and Research(12), CAR-T cell therapy research(11)

Publications126 total

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL
EClinicalMedicine·2023· 32 citedOpen Access
Electronic health records (EHRs) in clinical research and platform trials: Application of the innovative EHR-based methods developed by EU-PEARL
Journal of Biomedical Informatics·2023· 19 citedOpen Access
Supplementary Table Legends 1-3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 1 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Data from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Data from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 2 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 1 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 2 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table Legends 1-3 from Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
2023Open Access
Supplementary Table 3 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Figure 5 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Figure 4 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Methods from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Table 2 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Figure 2 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Figure Legends from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
Supplementary Figure 4 from Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Modesto Orozco(7), A. Nascimento(6), C. Jimenez‐Mallebrera(6), Marta Cascante(6), Josep Roca(6), C. Ortez(5), F. Javier Luque(5), Cristina Jou(4), Teresa Casserras(4), Àlvar Agustí(4), Francesco Falciani(4), Raquel Montero(3), Julio Montoya(3), Eduardo Ruiz‐Pesini(3), Rafael Artuch(3), Rosa Faner(3), Sonia Paco(3), Maria Angels Rodríguez(3), Josep Lluís Gelpí(3), Esther Barreiro(3)